Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

Y0001370

Olanzapine

European Pharmacopoeia (EP) Reference Standard

Synonyma:

2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen


About This Item

Empirický vzorec (Hillův zápis):
C17H20N4S
Číslo CAS:
Molekulová hmotnost:
312.43
Beilstein/REAXYS Number:
7655141
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

olanzapine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CN1CCN(CC1)C2=Nc3ccccc3Nc4sc(C)cc24

InChI

1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

InChI key

KVWDHTXUZHCGIO-UHFFFAOYSA-N

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Olanzapine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Skull and crossbones

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

target_organs

Central nervous system

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3


Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number

Je nám líto, ale pro tento produkt momentálně nemáme COA k dispozici online.

Potřebujete-li pomoc, obraťte se na Zákaznická podpora

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Zákazníci si také prohlíželi

Slide 1 of 5

1 of 5

Jacqueline Flank et al.
Pediatric blood & cancer, 62(3), 496-501 (2014-10-21)
This retrospective review provides preliminary data regarding the safety and efficacy of olanzapine for chemotherapy-induced vomiting (CIV) control in children. Children <18 years old who received olanzapine for acute chemotherapy-induced nausea and vomiting (CINV) control from December 2010 to August
Susan L McElroy et al.
Current psychiatry reports, 17(5), 35-35 (2015-03-23)
Psychopharmacologic treatment is playing a greater role in the management of patients with eating disorders. In this paper, we review randomized, placebo-controlled trials (RCTs) conducted in anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED), and other eating disorders
Hirotake Hida et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(3), 601-613 (2014-08-15)
Blonanserin differs from currently used serotonin 5-HT₂A/dopamine-D₂ receptor antagonists in that it exhibits higher affinity for dopamine-D₂/₃ receptors than for serotonin 5-HT₂A receptors. We investigated the involvement of dopamine-D₃ receptors in the effects of blonanserin on cognitive impairment in an
Erin Schwenger et al.
Clinical pharmacokinetics, 50(7), 415-428 (2011-06-10)
Olanzapine, a second-generation antipsychotic, is a first-line agent in the treatment of schizophrenia. The objective of this review was to determine whether olanzapine warrants clinical pharmacokinetic monitoring in patients with schizophrenia, using a previously published decision-making algorithm. Although olanzapine is
Karla Soares-Weiser et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 23(2), 118-125 (2012-05-29)
This comprehensive review and meta-analysis compared the effectiveness of olanzapine and other antipsychotics in schizophrenia treatment, defining effectiveness as time to all-cause medication discontinuation (primary) and as all-cause treatment discontinuation rates. This study examined randomized clinical trials (RCTs) and observational

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.